Search results
-
Verastem keeps investors waiting in KRAS
… It also represented a waning from the 52% ORR reported at ASCO 2025. So far, Verastem hasn’t revealed much from …
- 05/12/2026 - 15:40 -
An unexpected Serena knockback for Astra
… inhibitor, or continued on their original therapy. At ASCO 2025 Astra disclosed that median PFS in the …
- 05/05/2026 - 14:20 -
CCR8 promise and peril
… PD-1 MAb Pooled monotherapy & combo data at ASCO 2025: 6% ORR (4/62 patients) Innocare CM369 Monotherapy Monotherapy data at ASCO 2025 : mPFS 11.4 months in 12 CTCL patients HC …
- 05/19/2026 - 19:49 -
Kainova bigs up EP4 antagonism
… among 51 patients with metastatic colorectal cancer. ASCO 2025 saw data from Rottapharm’s vorbipiprant, in … Ph1/2 + balstilimab in pMMR/MSS colorectal cancer ASCO 2025 data: ORR 33% (3/9) in PD-L1 5% gastric cancer; … Ph1 in solid tumours began Jan 2025 TiP poster at ASCO 2025 OCT-598/ KNP-502 EP2/EP4 antagonist …
- 05/19/2026 - 19:49 -
CSPC looks for HER2 white space
… cancer in a phase I solid tumour trial presented at ASCO 2025. Meanwhile, among 64 HER2-overexpressing …
- 05/19/2026 - 19:49 -
J&J tries to outdo Tecvayli
… or AL amyloidosis Monotx (uncontrolled) Data at ASCO 2025: 100% ORR with RP2D in BCMA/GPRC5D-naive pts …
- 05/19/2026 - 19:49 -
Caribou finds a match
… up 25%, but later on Monday it was trading flat. Since ASCO 2025, where the Antler update had been expected before …
- 05/19/2026 - 19:49 -
Bispecific cytokine delivers for Innovent at last
… “We are marginally more positive on IBI363 after ASCO 2025, but note [that] IL-2 is not high on the …
- 05/19/2026 - 19:49 -
Few pancreatic Gleams of hope for Vyloy
… Solid tumours Monotx Gastric cancer data at ASCO 2025 Source: OncologyPipeline. …
- 05/19/2026 - 19:49 -
Takeda’s cancer prospects dim further
… mimetic Polycythemia vera Ph3 Verify presented at ASCO 2025, filing due in H2 2025 Licensed from …
- 05/19/2026 - 19:49
